Anti-FLAG Antibody Detection of HP-NAP for H. pylori Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing Helicobacter pylori infection are inadequate due to high costs, time-consuming processes, and potential for false results, and existing treatments do not effectively address the inflammatory damage caused by HP-NAP, a virulence factor produced by H. pylori.
Innovation Solution
A method using an ANTI-FLAG antibody to detect HP-NAP in test samples from subjects, which involves contacting the samples with the antibody and using techniques like western-blotting or ELISA to determine the presence of H. pylori, and administering the antibody to inhibit HP-NAP activity, potentially combined with anti-inflammatory agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gastric tissue culture is used for diagnosis, then H. pylori detection can be performed, but false positive or false negative results occur easily
Solution Approach 1:
The patent extracts the specific virulence factor HP-NAP from the complex bacterial culture process. Instead of culturing the entire bacterium and risking contamination or culture failure, the method directly detects the HP-NAP protein using antibodies, eliminating the complex operational steps of tissue culture while maintaining diagnostic reliability.
Solution Approach 2:
The patent introduces antibodies as an intermediary substance to detect HP-NAP. The antibody-antigen binding provides a reliable and specific detection mechanism that avoids the false results associated with direct bacterial culture, while simplifying the operational process to straightforward immunological assays.
2Reliability
If urea breath test with carbon isotopes is used, then H. pylori infection can be detected, but the cost is too high for developing countries
Solution Approach 1:
The patent employs relatively inexpensive antibody reagents and standard immunological assay techniques (ELISA, western blotting) that can be performed in basic laboratories. This replaces the expensive carbon isotope-based urea breath test with affordable antibody-based detection methods that maintain diagnostic accuracy while being accessible to developing countries.
3Measurement precision
If polymerase chain reaction (PCR) is used for diagnosis, then H. pylori detection sensitivity is improved, but the method is costly, time-consuming and not clinically applicable
Solution Approach 1:
The patent replaces the complex mechanical and thermal cycling process of PCR with a simpler immunological detection system using antibodies. The antibody-antigen binding occurs at standard incubation temperatures without requiring repeated heating and cooling cycles, dramatically reducing diagnosis time while maintaining high sensitivity and eliminating the need for specialized PCR equipment.
4Reliability
If existing treatments are used, then H. pylori infection can be addressed, but the inflammatory damage caused by HP-NAP is not effectively treated
Solution Approach 1:
The patent applies preliminary anti-action by using antibodies to block HP-NAP before it can bind to neutrophil receptors and trigger inflammatory responses. The antibody binds to HP-NAP epitopes, preventing the virulence factor from exerting its harmful effects on gastric mucosa, thereby treating the inflammatory damage at its source rather than merely suppressing symptoms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a fast, accurate diagnostic method for H. pylori infection and effectively inhibits the inflammatory responses triggered by HP-NAP, offering a potential treatment by blocking its activity.
Implementation Method 1
contacting the test sample with an ANTI-FLAG antibody; and detecting a binding of the ANTI-FLAG antibody of step (b) to HP-NAP produced by H. pylori in the test sample
Implementation Method 2
administering to the subject an effective amount of an ANTI-FLAG antibody, wherein the ANTI-FLAG antibody inhibits the activity of HP-NAP
Data Source
AI summary
The present invention provides methods for diagnosing and treating Helicobacter pylori infection by using a monoclonal antibody to detect Helicobacter pylori neutrophil-activating protein (HP-NAP) and inhibit the activity thereof. The monoclonal antibody is an ANTI-FLAG antibody that binds to a specific epitope on HP-NAP for the detection of HP-NAP in its native form or denatured form. Furthermore, the present invention uses the ANTI-FLAG antibody to block HP-NAP-induced production of reactive oxygen species by human neutrophils. Thus, the present invention can be applied in clinical diagnosis of Helicobacter pylori infection as well as treatment of the infection via inhibiting Helicobacter pylori-induced inflammation.